Novo Nordisk har i dag offentliggjort overordnede fase III-resultater (REDIFINE2) for CagriSema, som er en kombination af GLP-1 agonisten semaglutid og amylinanalogen cagrilinitid i en ugentlig injektion, og som undersøgte CagriSema til behandling af fedme og overvægt i voksne med type 2-diabetes.
Læs hele senioranalytiker Søren Løntoft Hansens aktienyt om Novo Nordisk her.
Alle aktiekurser er leveret af Refinitiv og er minimum 15 minutter forsinket. For yderligere information klik her.
Thomson Reuters Content is the intellectual property of Thomson Reuters Limited.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. Thomson Reuters trademarks, service marks, trade names and logos are registered trademarks or trademarks of the Thomson Reuters group of companies around the world.
Neither Thomson Reuters nor its third party content providers shall be liable for any errors, inaccuracies or delays in content, or for any actions taken in reliance thereon. THOMSON REUTERS EXPRESSLY DISCLAIMS ALL WARRANTIES, EXPRESSED OR IMPLIED, AS TO THE ACCURACY OF ANY THE CONTENT PROVIDED, OR AS TO THE FITNESS OF THE INFORMATION FOR ANY PURPOSE.
Further information about other Thomson Reuters services is available on Thomson Reuters' websites:
http://www.reuters.com and http://www.thomsonreuters.com
Thomson Reuters Ltd. provides quotes from the following stock exchanges: New York Stock Ex-change, NASDAQ OMX, Deutsche Börse AG, Hong Kong Stock Exchange
